

# Provider Network News

## Texas Medicaid Preferred Drug List (PDL) Changes Effective July 28, 2025

On July 28, 2025, Texas Medicaid Preferred Drug implemented the July 2025 PDL formulary changes at the direction of the Texas Vendor Drug Program.

ADALIMUMAB-ADAZ INJ, HADLIMA INJ, and SIMLANDI INJ have been added to the formulary as preferred products. Both HADLIMA INJ and SIMLANDI INJ are interchangeable biosimilars to the reference product HUMIRA.

Preferred Drug Status	
HUMIRA INJ	ADALIMUMAB-ADAZ INJ
	HADLIMA INJ
	SIMLANDI INJ

PYZCHIVA INJ and SELARSDI INJ have been added to the formulary as preferred products.

Non-Preferred Drug Status	PDL Formulary Alternatives (Interchangeable Biosimilars)
STELARA INJ	PYZCHIVA INJ
	SELARSDI IN

To view all changes to the PDL and their associated Prior Authorization criteria, please refer to the following links:

- [Formulary Drug Search | Vendor Drug Program](#)
- TX STAR CHIP—Prior Authorization Forms: [txstarchip.navitus.com/priorauthorizationforms](https://txstarchip.navitus.com/priorauthorizationforms)